With Low Percentage Of R&D Funding Going Toward NTDs, Some Pharmaceutical Companies Focus On Partnerships, Collaboration

The Guardian: Is it fair to accuse the pharma industry of neglecting tropical diseases?
“…Currently the biggest impetus for dealing with NTDs seems to come from partnerships. … There is some evidence to suggest the pharma industry uses partnerships to absolve itself of responsibility. Major companies are closing down their NTD R&D operations while opening up their compound libraries to partnerships, such as Novartis to the TB Alliance. … The solution for NTD drug R&D may not be partnerships alone, but must include cross-sector collaboration…” (Smedley, 10/15).